Collaboration Agreements
All Business Industries
PIERIS PHARMACEUTICALS, INC. (47) | Collaboration Agreements (9)
- Amendment No. 5, dated August 1, 2022, to the License and Collaboration Agreement, dated May 2, 2017, by and between Pieris Pharmaceuticals, Inc. and AstraZeneca AB (Filed With SEC on November 4, 2022)
- Amendment No. 3, dated June 9, 2022, to the License and Collaboration Agreement, dated May 2, 2017, by and between Pieris Pharmaceuticals, Inc. and AstraZeneca AB (Filed With SEC on August 4, 2022)
- Amendment No. 4, dated June 30, 2022, to the License and Collaboration Agreement, dated May 2, 2017, by and between Pieris Pharmaceuticals, Inc. and AstraZeneca AB (Filed With SEC on August 4, 2022)
- Research Collaboration and License Agreement, dated May 19, 2021, by and among Pieris Pharmaceuticals, Inc., Pieris Pharmaceuticals GmbH and Genentech, Inc (Filed With SEC on August 5, 2021)
- Amended and Restated License and Collaboration Agreement, dated March 24, 2021, by and between Pieris Pharmaceuticals, Inc. and Seagen Inc (Filed With SEC on May 17, 2021)
- Amendment No. 2, dated March 29, 2021, to the License and Collaboration Agreement, dated May 2, 2017, by and between Pieris Pharmaceuticals, Inc. and AstraZeneca AB (Filed With SEC on May 17, 2021)
- Clinical Trial Collaboration and Supply Agreement, dated August 10, 2020, by and between Pieris Pharmaceuticals, Inc. and Eli Lilly and Company (Filed With SEC on November 4, 2020)
- Amendment No. 1 to the February 8, 2018 License and Collaboration Agreement by and among Pieris Pharmaceuticals, Inc. and Pieris Pharmaceuticals GmbH and Seattle Genetics, Inc (Filed With SEC on August 10, 2020)
- Letter Amendment to the License and Collaboration Agreement by and between Les Laboratoires Servier, Institut de Recherches Internationales Servier, Pieris Pharmaceuticals, Inc.... (Filed With SEC on March 13, 2020)